Cargando…

Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

Nowadays; intravitreal anti-vascular endothelial growth factor (VEGF) drugs are considered the first-line therapeutic strategy for treating macular exudative diseases; including wet age-related macular degeneration (w-AMD) and diabetic macular edema (DME). Despite the important clinical achievements...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferro Desideri, Lorenzo, Traverso, Carlo Enrico, Nicolò, Massimo, Munk, Marion R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222467/ https://www.ncbi.nlm.nih.gov/pubmed/37242655 http://dx.doi.org/10.3390/pharmaceutics15051413

Ejemplares similares

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
por: Liberski, Sławomir, et al.
Publicado: (2022)

Intravitreal Faricimab for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B, et al.
Publicado: (2022)

Faricimab for Treatment-Resistant Diabetic Macular Edema
por: Rush, Ryan B, et al.
Publicado: (2022)

Machine Learning to Predict Faricimab Treatment Outcome in Neovascular Age-Related Macular Degeneration
por: Kikuchi, Yusuke, et al.
Publicado: (2023)

Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration
por: Leung, Ella H, et al.
Publicado: (2023)

One-Year Outcomes of Faricimab Treatment for Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
por: Rush, Ryan B
Publicado: (2023)

Efficacy, Durability and Safety of Faricimab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Oedema: Lessons Learned from Registration Trials
por: Larsen, Helene O., et al.
Publicado: (2023)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
por: Ohara, Hiromi, et al.
Publicado: (2023)

Short-Term Outcomes of Faricimab Treatment in Aflibercept-Refractory Eyes with Neovascular Age-Related Macular Degeneration
por: Kishi, Maya, et al.
Publicado: (2023)

Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration
por: Tamiya, Ryosuke, et al.
Publicado: (2023)

Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema
por: Kusuhara, Sentaro, et al.
Publicado: (2023)

One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema
por: Rush, Ryan B
Publicado: (2023)

Turnover of Microaneurysms After Intravitreal Injections of Faricimab for Diabetic Macular Edema
por: Takamura, Yoshihiro, et al.
Publicado: (2023)

TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
por: Khanani, Arshad M., et al.
Publicado: (2021)

Eligibility for faricimab in a real-world neovascular age-related macular degeneration population: a cross-sectional study
por: Jern, Iréne, et al.
Publicado: (2022)

Faricimab Effectively Resolves Intraretinal Fluid and Preserves Vision in Refractory, Recalcitrant, and Nonresponsive Neovascular Age-Related Macular Degeneration
por: Cheng, Anny M, et al.
Publicado: (2023)

The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
por: Khanani, Arshad M., et al.
Publicado: (2023)

Brolucizumab in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Ophthalmology and Diabetology Treatment Aspects
por: Garweg, Justus G., et al.
Publicado: (2023)

Visual and Anatomical Outcomes After Initial Intravitreal Faricimab Injection for Neovascular Age-Related Macular Degeneration in Patients with Prior Treatment History
por: Inoda, Satoru, et al.
Publicado: (2023)

Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy
por: Nair, Archana A, et al.
Publicado: (2022)

Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan
por: Mukai, Ryo, et al.
Publicado: (2023)

Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Kiss, Szilárd, et al.
Publicado: (2020)

Diabetic macular edema, retinopathy and age-related macular degeneration as inflammatory conditions
por: Das, Undurti N.
Publicado: (2016)

Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial
por: Sahni, Jayashree, et al.
Publicado: (2020)

Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat, Davis, et al.
Publicado: (2020)

Dysregulated Tear Film Proteins in Macular Edema Due to the Neovascular Age-Related Macular Degeneration Are Involved in the Regulation of Protein Clearance, Inflammation, and Neovascularization
por: Winiarczyk, Mateusz, et al.
Publicado: (2021)

Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006)

Treatment of neovascular age-related macular degeneration in patients with diabetes
por: Cummings, Michael, et al.
Publicado: (2008)

YOSEMITE and RHINE: Phase 3 Randomized Clinical Trials of Faricimab for Diabetic Macular Edema: Study Design and Rationale
por: Eter, Nicole, et al.
Publicado: (2021)

Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial
por: Khanani, Arshad M., et al.
Publicado: (2020)

Efficacy, durability, and safety of faricimab in patients from Asian countries with neovascular age-related macular degeneration: 1-Year subgroup analysis of the TENAYA and LUCERNE trials
por: Takahashi, Kanji, et al.
Publicado: (2023)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
por: Fong, Angie HC, et al.
Publicado: (2013)

Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations
por: Kodjikian, Laurent, et al.
Publicado: (2021)

Drusen characteristics of type 2 macular neovascularization in age-related macular degeneration
por: Ahmed, Daniel, et al.
Publicado: (2020)

Choroidal Modifications Preceding the Onset of Macular Neovascularization in Age-Related Macular Degeneration
por: Arrigo, Alessandro, et al.
Publicado: (2021)

Real-Life Management of Diabetic Macular Edema with Dexamethasone Intravitreal Implant: A Retrospective Analysis of Long-Term Clinical Outcomes
por: Nicolò, Massimo, et al.
Publicado: (2020)

Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
por: Zhou, Pengxiang, et al.
Publicado: (2021)

Drivers of and Barriers to Adherence to Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment Management Plans: A Multi-National Qualitative Study
por: Giocanti-Aurégan, Audrey, et al.
Publicado: (2022)

Radiation therapy for neovascular age-related macular degeneration
por: Petrarca, Robert, et al.
Publicado: (2011)

Experimental Models in Neovascular Age Related Macular Degeneration
por: Rastoin, Olivia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kuac5ao38qqnjr4kk9r2uauhlv